Holen Sie sich die Stockscreener-App
91.27
1.48%
1.485
Schlusskurs vom Vortag:
$89.78
Offen:
$90.13
24-Stunden-Volumen:
234.28K
Relative Volume:
0.29
Marktkapitalisierung:
$5.50B
Einnahmen:
$521.31M
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-190.89
EPS:
-0.4781
Netto-Cashflow:
$54.87M
1W Leistung:
+5.57%
1M Leistung:
-11.63%
6M Leistung:
+22.60%
1J Leistung:
+104.46%
1-Tages-Spanne:
$89.74
$92.72
1-Wochen-Bereich:
$84.33
$92.72
52-Wochen-Spanne:
$36.88
$109.28
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
91.12 | 5.42B | 521.31M | -23.36M | 54.87M | -0.4781 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.22 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.63 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.02 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.96 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.43 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Aug Patterns: Can Mirum Pharmaceuticals Inc benefit from deglobalization2026 Catalysts & Weekly Breakout Watchlists - baoquankhu1.vn
Does Advancing Brelovitug Into Late-Stage HDV Trials Change The Bull Case For Mirum Pharmaceuticals (MIRM)? - simplywall.st
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Mirum Pharmaceuticals at Leerink Conference: Strategic Growth Plans By Investing.com - Investing.com Canada
Mirum Pharmaceuticals at Citizens Life Sciences: Strategic Pipeline Advancements By Investing.com - Investing.com Canada
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Understanding the Setup: (MIRM) and Scalable Risk - Stock Traders Daily
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - MSN
Teachers Retirement System of The State of Kentucky Invests $1.08 Million in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) earnings expected to grow: What to know ahead of Q4 release - MSN
Mirum’s Brelovitug Phase 3 Milestones Reframe Rare Disease Growth Story - simplywall.st
Mirum Finishes Participant Enrollment and Screening for Liver Disease Research - Bitget
Mirum Completes Enrollment & Screening in Liver Disease Studies - Barchart.com
TD Asset Management Inc Buys Shares of 15,400 Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals provides Azure clinical program update for Brelovitug in chronic hepatitis delta virus - marketscreener.com
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus - marketscreener.com
Volatility Watch: Is Mirum Pharmaceuticals Inc a stock for growth or value investorsPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Evercore ISI raises Mirum Pharmaceuticals stock price target on pipeline progress - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Promising Biotech with 35.82% Upside Potential - DirectorsTalk Interviews
William Blair Investment Management LLC Acquires Shares of 313,259 Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Vanguard Group Inc. Sells 19,500 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
MIRM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Mirum Pharmaceuticals (MIRM) Is Down 12.8% After Shelf Filing For US$1.3 Billion Equity Issuance - simplywall.st
HC Wainwright Brokers Decrease Earnings Estimates for MIRM - MarketBeat
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Recent Share Price Volatility - simplywall.st
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Volatile Trading On Common Stock Offering News - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Mirum Pharmaceuticals Stock Drops 15% After Share Offering. Analysts Still Target $120 - TIKR.com
Mirum Pharmaceuticals Achieves 104.92% Return, Establishing Itself as a Multibagger Stock - Markets Mojo
Mirum Pharmaceuticals price target raised to $130 from $123 at Morgan Stanley - TipRanks
MIRM Mirum Pharmaceuticals, Inc. Feb 26 2026 Leerink Maintains Outperform - Meyka
Mirum Pharmaceuticals (MIRM) Narrowing Losses Challenge Bearish Profitability Narratives In FY 2025 Results - simplywall.st
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $117.00 at TD Cowen - MarketBeat
13 Analysts Have This To Say About Mirum Pharmaceuticals - Benzinga
Mirum Pharmaceuticals stock falls on R&D spending outlook, RBC reiterates Outperform - Investing.com Canada
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues - Finviz
Evercore ISI reiterates Mirum Pharmaceuticals stock rating at Outperform By Investing.com - Investing.com UK
Royal Bank Of Canada Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $128.00 - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down Following Weak Earnings - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Cut to $132.00 by Analysts at Citizens Jmp - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $125.00 Price Target at Stifel Nicolaus - MarketBeat
Mirum Pharmaceuticals: Nothing Stops This Train (But The Technicals) (NASDAQ:MIRM) - Seeking Alpha
RBC Lowers Price Target on Mirum Pharmaceuticals to $128 From $130, Keeps Outperform Rating - marketscreener.com
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update - BioSpace
Mirum Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates - Bitget
Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Mirum Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance - Intellectia AI
Mirum Pharmaceuticals Files For Offering Of Up To 8.96 Million Shares Of Common Stock By The Selling Stockholders - TradingView
Mirum (MIRM) Q4 2025 Earnings Call Transcript - AOL.com
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Mirum Pharmaceuticals, Inc. has officially registered a public offering plan of common stock initiated by selling shareholders. - Bitget
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):